A recent Nature Medicine study from researchers at the University of Toronto and the Hospital for Sick Children demonstrated targeted RNA sequencing performs on par with DNA-based diagnostics in cancer detection but with superior fusion gene identification and functional insights. Testing over 2,300 adult and pediatric cases predominantly with formalin-fixed paraffin-embedded samples, RNA-seq showed high success rates and sensitive detection of structural variants driving tumors, especially pediatric fusion-driven cancers. This highlights RNA-seq's potential as an independent precision oncology tool.